Canaccord Genuity Group Lowers AtriCure (NASDAQ:ATRC) Price Target to $52.00
AtriCure (NASDAQ:ATRC – Free Report) had its price objective reduced by Canaccord Genuity Group from $66.00 to $52.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a buy rating on the medical device company’s stock. Several other research analysts have also recently commented on the stock. Oppenheimer raised their […]
AtriCure (NASDAQ:ATRC – Free Report) had its price objective reduced by Canaccord Genuity Group from $66.00 to $52.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a buy rating on the medical device company’s stock. Several other research analysts have also recently commented on the stock. Oppenheimer raised their […]
